Avid to Develop Mapp Biopharmaceutical’s Antiviral Drug Candidate in Clinical

August 26, 2020
BioPharm International Editors

Mapp has selected Avid to provide process transfer, scale-up, and clinical manufacturing services for one of its development programs for a novel antiviral drug candidate.

Contract development and manufacturing organization (CDMO) Avid Bioservices announced on Aug. 26, 2020 that Mapp Biopharmaceutical, a pharmaceutical company located in San Diego, CA, has selected Avid to provide process transfer, scale-up, and clinical manufacturing services for one of Mapp’s development programs for a novel antiviral drug candidate.

“We are extremely delighted and honored that Mapp Biopharmaceutical, Inc. contracted Avid Bioservices as their CDMO to support the company’s antiviral program. Today, we are all too familiar with viral outbreaks and, as part of the scientific community, we are proud to leverage our expertise to support the prevention and treatment of challenging viruses,” said Timothy Compton, chief commercial officer of Avid, in the press release. “This agreement with Mapp Biopharmaceutical provides further evidence of the significant momentum that Avid’s business development team continues to generate toward our dual goals of revenue growth and customer base diversification. We are pleased to add Mapp to our growing list of customers. We are eager to get to work so that we can efficiently move toward CGMP [current good manufacturing practices] manufacturing runs that will support Mapp’s advancement of their product into clinical studies.”

“Mapp is happy to partner with Avid Bioservices to advance the development of our antiviral program towards IND [investigational new drug] and first-in-human evaluation,” added Dr. Ron Aimes, vice-president of Preclinical/Nonclinical Development and the program’s principal investigator at Mapp, in the press release. “Avid’s more than 20 years of experience in biologics manufacturing, positive track record with regulatory agencies, extensive capabilities, and manufacturing capacity will help us make this medical countermeasure available for the United States as well as patients around the globe quickly, safely, and efficiently.”

Source: Avid Bioservices